pSivida rises on Phase III uveitis data

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.79 (21%) to $4.49 on NASDAQ on Tuesday after its Medidur fluocinolone

Read the full 173 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE